Особенности генитального герпеса у женщин

1. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8): 964–73.
2. Kularatne RS, Muller EE, Maseko DV et al. Trends in the relative prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa, 2007–2015. PLoS One 2018; 13 (4): e0194125.
3. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11 (Suppl. 1): 24A–35A.
4. Cusini M, Ghislanzoni M. The importance of diagnosing genital herpes. J Antimicrob Chemother 2001; 47 (Suppl. T1): 9–16.
5. Кузьмин В.Н. Современный взгляд на клиническое течение, диагностику и терапию генитального герпеса у женщин. Consilium Medicum. 2014; 16 (6): 55–60. / Kuz'min V.N. Sovremennyi vzgliad na klinicheskoe techenie, diagnostiku i terapiiu genital'nogo gerpesa u zhenshchin. Consilium Medicum. 2014; 16 (6): 55–60. [in Russian]
6. Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections. Med Microbiol Immunol 2007; 196 (2): 89–94.
7. Baker DA. Consequences of herpes simplex virus in pregnancy and their prevention. Curr Opin Infect Dis 2007; 20 (1): 73–6.
8. Enright AM, Prober CG. Neonatal herpes infection: diagnosis, treatment and prevention. Semin Neonatol 2002; 7 (4): 283–91.
9. Fatahzadeh M et al. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and  management. J Am Acad Dermatol 2007; 57: 737–6.
10. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines. Centres for Disease Control, www.cdc.gov (2015, accessed 12 November 2015).
11. Patton DL, Thwin SS, Meier A et al. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 2000; 183 (4): 967–73. DOI: 10.1067/mob.2000.108857
12. Xu F. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8): 964–73.
13. Vauloup-Fellous C. Genital herpes and pregnancy: serological and molecular diagnostic tools. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF). Gynecol Obstet Fertil Senol 2017; 45: 655–63.
14. Ashley RL. Genital herpes. Type-specific antibodies for diagnosis and management. Dermatol Clin 1998; 16 (4): 789–93. XIII-XIV.
15. Инструкция по медицинскому применению лекарственного препарата Валвир. / Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Valvir. [in Russian]
16. Горячкина М.В., Белоусова Т.А., Эпизодическая и супрессивная терапия простого герпеса ациклическими нуклеозидами. Клин. дерматология и венерология. 2014; (4): 68–74. / Goryachkina M.V., Belousova T.A., Epizodicheskaya i supressivnaya terapiya prostogo gerpesa aciklicheskimi nukleozidami. Klin. dermatologiya i venerologiya. 2014; (4): 68–74. [in Russian]
17. Patel R, Bodsworth NJ, Woolley P et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997; 73: 105–9.
18. Клинические рекомендации по ведению больных с генитальным герпесом. М., 2012. / Klinicheskie rekomendacii po vedeniyu bolnyh s genitalnym gerpesom. M., 2012. [in Russian]
19. Patel R, Alderson S, Geretti A et al. IUSTI/WHO Europe. European guideline for the management of genital herpes, 2010. Int J STD AIDS 2011; 22 (1): 1–10.
20. Произведено в Болгарии [15].
21. Имеется ввиду снижение кратности/частоты приема по сравнению с ацикловиром.

________________________________________________

1. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8): 964–73.
2. Kularatne RS, Muller EE, Maseko DV et al. Trends in the relative prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa, 2007–2015. PLoS One 2018; 13 (4): e0194125.
3. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11 (Suppl. 1): 24A–35A.
4. Cusini M, Ghislanzoni M. The importance of diagnosing genital herpes. J Antimicrob Chemother 2001; 47 (Suppl. T1): 9–16.
5.  Kuz'min V.N. Sovremennyi vzgliad na klinicheskoe techenie, diagnostiku i terapiiu genital'nogo gerpesa u zhenshchin. Consilium Medicum. 2014; 16 (6): 55–60. [in Russian]
6. Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections. Med Microbiol Immunol 2007; 196 (2): 89–94.
7. Baker DA. Consequences of herpes simplex virus in pregnancy and their prevention. Curr Opin Infect Dis 2007; 20 (1): 73–6.
8. Enright AM, Prober CG. Neonatal herpes infection: diagnosis, treatment and prevention. Semin Neonatol 2002; 7 (4): 283–91.
9. Fatahzadeh M et al. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and  management. J Am Acad Dermatol 2007; 57: 737–6.
10. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines. Centres for Disease Control, www.cdc.gov (2015, accessed 12 November 2015).
11. Patton DL, Thwin SS, Meier A et al. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 2000; 183 (4): 967–73. DOI: 10.1067/mob.2000.108857
12. Xu F. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296 (8): 964–73.
13. Vauloup-Fellous C. Genital herpes and pregnancy: serological and molecular diagnostic tools. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF). Gynecol Obstet Fertil Senol 2017; 45: 655–63.
14. Ashley RL. Genital herpes. Type-specific antibodies for diagnosis and management. Dermatol Clin 1998; 16 (4): 789–93. XIII-XIV.
15. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Valvir. [in Russian]
16. Goryachkina M.V., Belousova T.A., Epizodicheskaya i supressivnaya terapiya prostogo gerpesa aciklicheskimi nukleozidami. Klin. dermatologiya i venerologiya. 2014; (4): 68–74. [in Russian]
17. Patel R, Bodsworth NJ, Woolley P et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997; 73: 105–9.
18. Klinicheskie rekomendacii po vedeniyu bolnyh s genitalnym gerpesom. M., 2012. [in Russian]
19. Patel R, Alderson S, Geretti A et al. IUSTI/WHO Europe. European guideline for the management of genital herpes, 2010. Int J STD AIDS 2011; 22 (1): 1–10.
20. Произведено в Болгарии [15].
21. Имеется ввиду снижение кратности/частоты приема по сравнению с ацикловиром.

Е.В.Дворянкова1,2, Л.Р.Сакания3, О.Р.Бабаев3, В.В.Шахзадов3, И.М.Корсунская*1

1. ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, к. 1;
2. Семейный медицинский центр «Пангея». 107061, Россия, Москва, ул. Большая Черкизовская, д. 5, к. 8, стр. 1;
3. ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский пр-т, д. 17
*marykor@bk.ru

________________________________________________

E.V.Dvoriankova1,2, L.R.Sakaniia3, O.R.Babaev3, V.V.Shakhzadov3, I.M.Korsunskaia*1

1. Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, k. 1;
2. Family Medical Center "Pangea". 107061, Russian Federation, Moscow, ul. Bol'shaia Cherkizovskaia, d. 5, k. 8, str. 1;
3. Moscow Scientific and Practical Center of Dermatology and Venereology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy pr-t, d. 17
*marykor@bk.ru